BioPharmSignal logoBioPharmSignal

Biotech News

CVRx Reports Third Quarter 2026 Financial and Operating Results

CVRx (CVRX)CVRxEarnings

MINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and

Related news

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

STIMNeuronetics2026-11-04 12:50 EST

Neuronetics Reports Third Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-10-21 12:30 EST

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

ALGSAligos Therapeutics2026-11-06 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

MNKDMannKind2026-11-05 21:01 EST

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

ALTAltimmune2026-11-05 13:00 EST

Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

PRCTPROCEPT BioRobotics2026-11-04 21:05 EST

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACHCAcadia Healthcare2026-11-04 21:05 EST

Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance

View all latest news

CVRx

Cardiovascular Neuromodulation CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression. Barostim Platform Barostim is the company's implantable...

Recent company news

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

CVRXCVRx2026-11-02 21:02 EST

CVRx to Participate in Upcoming Investor Conferences

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

CVRXCVRx2026-09-29 20:30 EST

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRXCVRx2026-09-21 20:08 EST

CVRx Appoints John Landry as Chief Financial Officer

Stock data

Close
1.47 USD
Market cap
144.09M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States